Statistical issues in randomized trials of cancer screening

被引：37

作者：

Baker S.G. ^{[1
]}

Kramer B.S. ^{[2
]}

Prorok P.C. ^{[1
]}

机构：

[1] Division of Cancer Prevention, National Cancer Institute, Bethesda, MD

[2] Office of Disease Prevention, National Institutes of Health, Bethesda, MD

来源：

BMC Medical Research Methodology | / 2卷 / 1期

关键词：

Cancer Screening; Cancer Death; Breast Cancer Screening; Cancer Screening Trial; Computing Confidence Interval;

D O I：

10.1186/1471-2288-2-11

中图分类号：

学科分类号：

摘要：

Background: The evaluation of randomized trials for cancer screening involves special statistical considerations not found in therapeutic trials. Although some of these issues have been discussed previously, we present important recent and new methodologies. Methods: Our emphasis is on simple approaches. Results: We make the following recommendations: (1) Use death from cancer as the primary endpoint, but review death records carefully and report all causes of death (2) Use a simple "causal" estimate to adjust for nonattendance and contamination occurring immediately after randomization (3) Use a simple adaptive estimate to adjust for dilution in follow-up after the last screen Conclusion: The proposed guidelines combine recent methodological work on screening endpoints and noncompliance/contamination with a new adaptive method to adjust for dilution in a study where follow-up continues after the last screen. These guidelines ensure good practice in the design and analysis of randomized trials of cancer screening.

引用

页码：1 / 7

页数：6

共 26 条

[1]

Etzioni R.D., Connor R.J., Prorok P.C., Self S.G., Design and analysis of cancer screening trials, Statistical Methods in Medical Research, 4, pp. 3-17, (1995)

[2]

Connor R.J., Prorok P.C., Issues in the mortality analysis of randomized controlled trials of cancer screening, Controlled Clinical Trials, 15, pp. 81-99, (1994)

[3]

Black W.C., Haggstrom D.A., Welch H.G., All-cause mortality in randomized trials of cancer screening, Journal of the National Cancer Institute, 94, pp. 167-173, (2002)

[4]

Hardcastle J.D., Chamberlain J.O., Robinson M.H., Moss S.M., Amar S.S., Balfour T.W., James P.D., Mangham C.M., Randomised controlled trial of faecal-occult-blood screening for colorectal cancer, Lancet, 348, pp. 1472-1477, (1996)

[5]

Glasziou P.P., Meta-analysis adjusting for compliance: The example of screening for breast cancer, Journal of Clinical Epidemiology, pp. 1251-1256, (1992)

[6]

Baker S.G., Lindeman K.S., The paired availability design: A proposal for evaluating epidural analgesia during labor, Statistics in Medicine, 13, pp. 2269-2278, (1994)

[7]

Angrist J.D., Imbens G.W., Rubin D.R., Identification of causal effects using instrumental variables, Journal of the American Statistical Association, 92, pp. 444-455, (1996)

[8]

Baker S.G., Analysis of survival data from a randomized trial with all-or-none compliance

[9]

estimating the cost-effectiveness of a cancer screening program, Journal of the American Statistical Association, 93, pp. 929-934, (1998)

[10]

Cuzick J., Edward R., Segnan N., Adjusting for non-compliance and contamination in randomized clinical trials, Statistics in Medicine, 16, pp. 1017-1029, (1997)

← 1 2 3 →